Literature DB >> 10638234

[Epidemic outbreak of tularemia in Palencia].

C Andrés Puertas1, M L Mateos Baruque, I Burón Lobo, M J González Megido, C Rebollo Cuadrado, L A Sangrador Arenas.   

Abstract

BACKGROUND: Tularemia can become a health problem after its recent emergence in Spain.
OBJECTIVE: To describe the clinico-epidemiologic characteristics of a tularemia outbreak occurred in Palencia (October 1997 to March 1998).
DESIGN: Case-control study.
MATERIAL AND METHODS: A clinico-epidemiologic survey was conducted. The Chi square test and the Student "t" test were used and a logistic regression analysis was made. The diagnosis was made by serology (microagglutination or macroagglutination) or culture.
RESULTS: There were 151 cases; 74.5% of cases were confirmed or likely. The ulceroglandular was the most common clinical form of the disease (49%) and 23.2% of patients required hospital admission; 93.4% of patients had exposure to hares, and 86.7% of them handled them. Higher risk practices included skinning (adjusted OR: 3.9; 95% CI [1.03-14.7]; p = 0.04) and cutting/cooking (adjusted OR: 2.7; 95% CI [1.01-6.7]; p = 0.03). Streptomycin therapy was used for 51.6% of cases.
CONCLUSIONS: The clinico-epidemiologic surveillance of this disease in Spain is necessary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10638234

Source DB:  PubMed          Journal:  Rev Clin Esp        ISSN: 0014-2565            Impact factor:   1.556


  2 in total

Review 1.  The status of tularemia in Europe in a one-health context: a review.

Authors:  G Hestvik; E Warns-Petit; L A Smith; N J Fox; H Uhlhorn; M Artois; D Hannant; M R Hutchings; R Mattsson; L Yon; D Gavier-Widen
Journal:  Epidemiol Infect       Date:  2014-09-30       Impact factor: 4.434

2.  Development of a multitarget real-time TaqMan PCR assay for enhanced detection of Francisella tularensis in complex specimens.

Authors:  Jessica L Versage; Darlena D M Severin; May C Chu; Jeannine M Petersen
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.